 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...8788899091929394959697...132133» |
- | everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion date, Combination therapy: Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Mar 1, 2019
P1/2, N=103, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Jan 2019 --> Dec 2019
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: EVERIMMUN: Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=112, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial completion date: Jan 2019 --> Dec 2019 Trial completion date: Dec 2020 --> May 2022 | Trial primary completion date: May 2020 --> May 2022
- everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Monotherapy: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma (clinicaltrials.gov) - Feb 27, 2019
P2, N=4, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial completion date: Dec 2020 --> May 2022 | Trial primary completion date: May 2020 --> May 2022 Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Combination therapy, Metastases: A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment (clinicaltrials.gov) - Feb 27, 2019
P1b/2, N=173, Completed, Sponsor: Eisai Inc.
Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020 Active, not recruiting --> Completed | Trial completion date: May 2017 --> Feb 2018
- | everolimus / Generic mfg.
Clinical, P1 data, Journal: Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. (Pubmed Central) - Feb 26, 2019
P1/2
Currently, the here selected combination is being evaluated in a phase II clinical trial. TRIAL REGISTRATION: NCT01462214.
- | temozolomide / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Trial completion date, Metastases: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) (clinicaltrials.gov) - Feb 25, 2019
P2, N=38, Active, not recruiting, Sponsor: Haukeland University Hospital
TRIAL REGISTRATION: NCT01462214. Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial completion date: Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant (clinicaltrials.gov) - Feb 22, 2019
P4, N=120, Completed, Sponsor: Ronaldo de Matos Esmeraldo, MD
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed | Trial completion date: Aug 2015 --> Jul 2017
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Feb 22, 2019
P1/2, N=35, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | Trial completion date: Aug 2015 --> Jul 2017 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Mekinist (trametinib) / Novartis, BeiGene
Enrollment change, Trial termination: GSK1120212 Rollover Study (clinicaltrials.gov) - Feb 19, 2019
P2, N=159, Terminated, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 N=250 --> 159 | Completed --> Terminated; Company Decision
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) (clinicaltrials.gov) - Feb 16, 2019
P2, N=48, Recruiting, Sponsor: Fox Chase Cancer Center
N=250 --> 159 | Completed --> Terminated; Company Decision Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Dec 2019
- || telaglenastat (CB-839) / Calithera
Enrollment closed, Combination therapy, Metastases: ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Feb 15, 2019
P2, N=63, Active, not recruiting, Sponsor: Calithera Biosciences, Inc
Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Dec 2019 Recruiting --> Active, not recruiting
- | everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion date, Trial primary completion date, Post-transplantation: TEAMMATE: Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score (clinicaltrials.gov) - Feb 15, 2019
P3, N=210, Recruiting, Sponsor: Boston Children
Recruiting --> Active, not recruiting Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
- | fulvestrant / Generic mfg.
Trial completion, Real-world evidence, Real-world, Metastases: Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients (clinicaltrials.gov) - Feb 15, 2019
P=N/A, N=131, Completed, Sponsor: Fudan University
Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2022 Active, not recruiting --> Completed
- | dexamethasone / Generic mfg., everolimus / Generic mfg.
New P3 trial: MIST: Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer (clinicaltrials.gov) - Feb 15, 2019
P3, N=279, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- ||| everolimus / Generic mfg.
Biomarker, Enrollment change, Metastases: Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Feb 12, 2019
P2, N=20, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed N=40 --> 20
- || carboplatin / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer (clinicaltrials.gov) - Feb 11, 2019
P2, N=72, Recruiting, Sponsor: Amy Tiersten
N=40 --> 20 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | itacitinib (INCB039110) / Incyte
Enrollment open, Combination therapy: Itacitinib + Everolimus in Hodgkin Lymphoma (clinicaltrials.gov) - Feb 8, 2019
P1/2, N=28, Recruiting, Sponsor: University of Pennsylvania
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- | Kisqali (ribociclib) / Novartis
New P1 trial, Combination therapy: A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (clinicaltrials.gov) - Feb 8, 2019
P1, N=24, Recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
- | Farydak (panobinostat) / Secura Bio
Trial initiation date, Combination therapy: A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas (clinicaltrials.gov) - Feb 7, 2019
P2, N=32, Recruiting, Sponsor: University of Michigan Rogel Cancer Center
Not yet recruiting --> Recruiting Initiation date: Dec 2018 --> Mar 2019
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date: RAD001 for Patients With Radioiodine Refractory Thyroid Cancer (clinicaltrials.gov) - Feb 7, 2019
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Dec 2018 --> Mar 2019 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | simvastatin / Generic mfg.
Trial completion date, Trial primary completion date: Safety of Simvastatin in LAM and TSC (clinicaltrials.gov) - Feb 6, 2019
P1/2, N=10, Active, not recruiting, Sponsor: University of Pennsylvania
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: Jan 2018 --> Dec 2019
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Sequential Therapy in Metastatic Renal Cell Carinoma (clinicaltrials.gov) - Feb 6, 2019
P2, N=22, Completed, Sponsor: Central European Society for Anticancer Drug Research
Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: Jan 2018 --> Dec 2019 Active, not recruiting --> Completed | N=100 --> 22 | Trial completion date: May 2016 --> Sep 2016 | Trial primary completion date: May 2016 --> Sep 2016
- ||| everolimus / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score (clinicaltrials.gov) - Feb 5, 2019
P2, N=17, Completed, Sponsor: Yale University
Active, not recruiting --> Completed | N=100 --> 22 | Trial completion date: May 2016 --> Sep 2016 | Trial primary completion date: May 2016 --> Sep 2016 Active, not recruiting --> Completed | N=66 --> 17 | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Jul 2017
- || Enrollment change, Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Feb 5, 2019
P=N/A, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=66 --> 17 | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Jul 2017 N=320 --> 500 | Trial completion date: Dec 2019 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Jan 2023
- | Envarsus (LCP-Tacro) / Asahi Kasei
Enrollment closed: Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=40, Active, not recruiting, Sponsor: Medical University of South Carolina
N=320 --> 500 | Trial completion date: Dec 2019 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Jan 2023 Recruiting --> Active, not recruiting
- || Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy: Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL (clinicaltrials.gov) - Jan 31, 2019
P1, N=45, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| everolimus / Generic mfg.
Enrollment closed: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment (clinicaltrials.gov) - Jan 30, 2019
P3, N=206, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | everolimus / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, PK/PD data, Journal: Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. (Pubmed Central) - Jan 29, 2019
Pharmacokinetically-targeted dosing appears to increase everolimus tolerability. This finding may be applicable to other patient populations.
- | cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
Enrollment open: LITMMUS-MGH: Liver Transplantation With Tregs at MGH (clinicaltrials.gov) - Jan 25, 2019
P1/2, N=9, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This finding may be applicable to other patient populations. Not yet recruiting --> Recruiting
- | everolimus / Generic mfg., sirolimus / Generic mfg., itraconazole / Generic mfg.
Trial completion date, Trial primary completion date: Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=126, Recruiting, Sponsor: Radboud University
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Jan 23, 2019
P2, N=31, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Recruiting --> Active, not recruiting | N=22 --> 31
- | everolimus / Generic mfg.
Clinical, P2 data, Journal, Combination therapy: A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913. (Pubmed Central) - Jan 19, 2019
Combining everolimus with conventional chemoradiation leads to increased treatment-related toxicities and did not improve PFS in patients with newly diagnosed glioblastoma. Although the MST in patients receiving everolimus was comparable to contemporary studies, it was inferior to the control in this randomized study.
- | Sutent (sunitinib) / Pfizer
Enrollment closed, Enrollment change, Surgery, Metastases: Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery (clinicaltrials.gov) - Jan 17, 2019
P2, N=16, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Although the MST in patients receiving everolimus was comparable to contemporary studies, it was inferior to the control in this randomized study. Recruiting --> Active, not recruiting | N=120 --> 16
- ||||| everolimus / Generic mfg., exemestane / Generic mfg.
Enrollment closed, Enrollment change, Combination therapy, Metastases: EVEREXES: Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jan 15, 2019
P3, N=236, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=120 --> 16 Recruiting --> Active, not recruiting | N=400 --> 236
- | New P1/2 trial, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker: FUSCC Refractory TNBC Umbrella (FUTURE) (clinicaltrials.gov) - Jan 15, 2019
P1/2, N=140, Recruiting, Sponsor: Fudan University
- | bortezomib / Generic mfg., everolimus / Generic mfg.
P1 data, Journal, Combination therapy: A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. (Pubmed Central) - Jan 13, 2019
In conclusion, the combination of everolimus and bortezomib results in dose limiting thrombocytopenia, but is tolerable. This combination has limited clinical activity in heavily pretreated NHL.
- | Mycobutin (rifabutin) / Pfizer, Lupin
Biomarker, Enrollment closed: TBHDT: TB Host Directed Therapy (clinicaltrials.gov) - Jan 10, 2019
P2, N=200, Active, not recruiting, Sponsor: The Aurum Institute NPC
This combination has limited clinical activity in heavily pretreated NHL. Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Trial initiation date: A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) (clinicaltrials.gov) - Jan 10, 2019
P3, N=26, Not yet recruiting, Sponsor: Yonsei University
Recruiting --> Active, not recruiting Initiation date: Jun 2018 --> Jan 2019
- | everolimus / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Open-label Study on Treatment of Primary Aldosteronism With Everolimus (clinicaltrials.gov) - Jan 9, 2019
P2, N=12, Completed, Sponsor: University Hospital, Basel, Switzerland
Initiation date: Jun 2018 --> Jan 2019 Recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
- || camizestrant (AZD9833) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) - Jan 9, 2019
P1, N=165, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018 Trial completion date: Jun 2020 --> Nov 2021 | Trial primary completion date: Jun 2020 --> Nov 2021
- | everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
New P4 trial, Combination therapy: OPTIMIZE: RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients (clinicaltrials.gov) - Jan 9, 2019
P4, N=374, Not yet recruiting, Sponsor: University Medical Center Groningen
- | everolimus / Generic mfg.
New P1/2 trial: RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (clinicaltrials.gov) - Jan 8, 2019
P1/2, N=40, Not yet recruiting, Sponsor: Boston Children’s Hospital
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date: NFC-RAD001: Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas (clinicaltrials.gov) - Jan 8, 2019
P2, N=23, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial completion date: Jun 2020 --> Nov 2021 | Trial primary completion date: Jun 2020 --> Nov 2021 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Combination therapy, Metastases: KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jan 8, 2019
P3, N=1050, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Apr 2019 Trial completion date: Apr 2020 --> Feb 2021
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Jan 8, 2019
P2, N=22, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Apr 2020 --> Feb 2021 Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2019 --> May 2019
- | Kisqali (ribociclib) / Novartis
Trial completion date, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jan 8, 2019
P2, N=76, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2019 --> May 2019 Trial completion date: Aug 2023 --> Aug 2022
- | everolimus / Generic mfg.
Journal: Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. (Pubmed Central) - Jan 5, 2019
Trial completion date: Aug 2023 --> Aug 2022 No abstract available
- || everolimus / Generic mfg., bendamustine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Jan 4, 2019
P1, N=20, Completed, Sponsor: University of California, Davis
No abstract available Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
- | cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
Trial completion date, Trial primary completion date: LITMMUS-UCSF: Liver Transplantation With Tregs at UCSF (clinicaltrials.gov) - Dec 28, 2018
P1/2, N=9, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025
- | cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
Trial completion date, Trial primary completion date: LITMMUS-MGH: Liver Transplantation With Tregs at MGH (clinicaltrials.gov) - Dec 28, 2018
P1/2, N=9, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025 Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025